Camrelizumab Combined with Radiotherapy Treating Locally Advanced Non-Small Cell Lung Cancer that has Failed Chemotherapy: A Case Report |Biomedgrid

Background: Recent advances in immunotherapy have led to a paradigm shift in lung cancer treatment, as well as treatment for several other solid tumors, in which immune checkpoint inhibitors are the most widely applied. Currently, the standard treatment for inoperable, locally advanced non-small cell lung cancer (NSCLC) is concurrent radiochemotherapy followed by 1 year of consolidation therapy with duvalizumab. However, for various reasons, only 20%-25% of patients with locally advanced NSCLC in China have undergone standardized treatment. Instead, a large number of patients have been treated with sequential chemoradiotherapy as an alternative option. However, there is no consensus regarding how to perform systemic treatment if/when chemotherapy is ineffective. We present a case of stage IIIB lung adenocarcinoma in which chemotherapy failed.